This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.15% per year. These returns cover a period from January 1, 1988 through June 3, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Falling Earnings Estimates Signal Weakness Ahead for Mylan (MYL)
by Zacks Equity Research
Mylan (MYL) has witnessed a significant price decline in the past four weeks, and is seeing negative earnings estimate revisions as well.
Top Ranked Momentum Stocks to Buy for March 20th
by Zacks Equity Research
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, March 20th
Dr. Reddy's (RDY) Earnings and Revenues Improve Y/Y in Q3
by Zacks Equity Research
Dr. Reddy's earnings and sales rise year over year in the third-quarter of fiscal 2019.
Dr. Reddy's (RDY) Earnings Rise in Q3, Sales Increase Y/Y
by Zacks Equity Research
Dr. Reddy???s earnings and sales increase year over year in the third quarter of fiscal 2019.
Dr. Reddy's (RDY) to Report Q3 Earnings: What's in Store?
by Zacks Equity Research
Dr. Reddy's has launched few generics which should add to revenues of the company when the company releases its third-quarter fiscal 2019 results.
Akorn (AKRX) Gets FDA Warning Letter for Illinois Facility
by Zacks Equity Research
Akorn, Inc. (AKRX) suffers a setback with the FDA handing over a warning letter post an inspection of its Illinois manufacturing facility in April and May of 2018.
Top-Ranked Sector ETFs & Stocks to Buy for 2019
by Sweta Killa
Investors could be well served by ETFs and stocks from top-ranked sectors.
VIVUS (VVUS) Banks on New Drug Pancreaze, Qsymia Lacks Luster
by Zacks Equity Research
Although VIVUS (VVUS) is struggling with its legacy products, promotional initiatives and addition of cash-flow positive assets bode well for the company.
Teva (TEVA) Ends Dispute with Amgen Over Generic Sensipar
by Zacks Equity Research
Teva (TEVA) ends an ongoing patent dispute with Amgen over generic Sensipar by making an undisclosed payment.
The Zacks Analyst Blog Highlights: Internet Initiative Japan, Sony, Ingersoll-Rand, HDFC Bank and Dr. Reddy's Laboratories
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Internet Initiative Japan, Sony, Ingersoll-Rand, HDFC Bank and Dr. Reddy's Laboratories
Generic Industry on Path to Recovery: 3 Hot Picks for 2019
by Zacks Equity Research
The stability in the industry sets the stage for players to get back on growth track. Here we discuss three stocks picks from the industry.
5 ADRs That More Than Doubled the S&P 500 in 2018
by Swarup Gupta
Japan, Ireland and India's economies offer a glimmer of hope since they are expected to perform well in 2019
Highlighted as Zacks Bull and Bear of the Day Dr. Reddy???s Laboratories, Dillard???s, Facebook, Netflix and Amazon
by Zacks Equity Research
Highlighted as Zacks Bull and Bear of the Day Dr. Reddy???s Laboratories, Dillard???s, Facebook, Netflix and Amazon
Bull of the Day: Dr. Reddy's Laboratories
by David Borun
This vertically integrated pharmaceutical company produces exactly the drugs the world needs most.
Zacks.com featured highlights include: Abercrombie, Dr. Reddy???s, Cree, Otter and Shenandoah
by Zacks Equity Research
Zacks.com featured highlights include: Abercrombie, Dr. Reddy???s, Cree, Otter and Shenandoah
Bet on These 5 Low-Beta Stocks to Fight Market Volatility
by Zacks Equity Research
We develop an investment strategy that shows low-beta stocks can be rewarding if some parameters are considered.
Generic Drugmakers Down on Allegations of Price Fixing
by Zacks Equity Research
An article in The Washington Post levels charges of price fixing against several generic drugmakers, driving their shares down.
The Zacks Analyst Blog Highlights: Anthem, HCA, Dr. Reddy's and UnitedHealth
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Anthem, HCA, Dr. Reddy's and UnitedHealth
Healthcare Takes Wall Street Lead: 4 Picks
by Tirthankar Chakraborty
Continuous innovation and research in the field of biotechnology and an increasingly aged population in the United States are helping whet appetite for healthcare shares.
Zacks.com highlights: Marcus, Papa Murphy's Holdings, Dr. Reddy's Laboratories, Tesla and Spirit Airlines
by Zacks Equity Research
Zacks.com highlights: Marcus, Papa Murphy's Holdings, Dr. Reddy's Laboratories, Tesla and Spirit Airlines
Lilly (LLY) Hits Fresh High: Is There Still Room to Run?
by Zacks Equity Research
Lilly (LLY) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
5 Low-Beta Stocks to Weather Market Volatility
by Zacks Equity Research
We create a strategy which shows that handsome returns can also be generated from less risky stocks.
New Strong Buy Stocks for November 26th
by Tirthankar Chakraborty
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Monday
J&J Gets Positive CHMP Opinion for Prostate Cancer Treatment
by Zacks Equity Research
Johnson & Johnson's (J&J) apalutamide gets positive CHMP opinion for the treatment of adult patients with non-metastatic castration-resistant prostate cancer.
Dr. Reddy's (RDY) Earnings and Revenues Improve Y/Y in Q2
by Zacks Equity Research
Dr. Reddy's (RDY) surpasses earnings and revenue estimates on strength across segments in the second quarter of fiscal 2019.